The rise in GLP-1 use among young women raises concerns about contraceptive efficacy and potential pregnancy risks. Learn ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Pop quiz: would you prefer to take a medication as a pill or inject yourself with it? Somehow, I suspect that the vast ...

It would be the first obesity-targeted GLP-1 in pill form. The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

It would be the first obesity-targeted GLP-1 in pill form. The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

The U.S. FDA has accepted the NDA for an oral formulation of Novo Nordisk A/S’s Wegovy (semaglutide) in treating obesity. If ...